The relatively cheap and still primary method is CA125 serial testing, supplemented by transvaginal ultrasound; however, CA125 does not cover the whole spectrum of epithelial ovarian cancer pathology due to low accuracy for early-stage HGSOC and borderline and mucinous cancers, as well as false positive results in some benign tumors. Here, MUC16 is linked to benign neoplasm.